Literature DB >> 34629718

Quality of Life and Cost Considerations: Y-90 Radioembolization.

Stephen J Williams1, William S Rilling1, Sarah B White1.   

Abstract

Objective  Transarterial radioembolization (TARE) offers a minimally invasive and safe treatment option for primary and metastatic hepatic malignancies. The benefits of TARE are manifold including prolonged overall survival, low associated morbidities, and improved time to progression allowing prolonged treatment-free intervals. The rapid development of new systemic therapies including immunotherapy has radically changed the treatment landscape for primary and metastatic liver cancer. Given the current climate, it is critical for interventional oncologists to understand the benefits of TARE relative to these other therapies. Therefore, this report aims to review quality-of-life outcomes and the cost comparisons of TARE as compared with systemic therapies. Thieme. All rights reserved.

Entities:  

Keywords:  health-related quality of life; hepatocellular carcinoma; interventional radiology; transarterial chemoembolization; transarterial radioembolization; yttrium 90

Year:  2021        PMID： 34629718      PMCID： PMC8497083          DOI： 10.1055/s-0041-1735570

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN： 0739-9529            Impact factor:   1.780


  37 in total

1.  Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada.

Authors:  Noemi Muszbek; Sonalee Shah; Stuart Carroll; Heather McDonald; Peter Dale; Jean Maroun; Jennifer Knox
Journal:  Curr Med Res Opin       Date:  2008-12       Impact factor: 2.580

2.  Outpatient single-session yttrium-90 glass microsphere radioembolization.

Authors:  Vanessa L Gates; Karen G Marshall; Krystina Salzig; Melissa Williams; Robert J Lewandowski; Riad Salem
Journal:  J Vasc Interv Radiol       Date:  2013-12-12       Impact factor: 3.464

3.  Cost-effectiveness of selective internal radiation therapy using yttrium-90 resin microspheres in treating patients with inoperable colorectal liver metastases in the UK.

Authors:  B Pennington; R Akehurst; H Wasan; B Sangro; A S Kennedy; K Sennfält; L Bester
Journal:  J Med Econ       Date:  2015-06-09       Impact factor: 2.448

4.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

5.  Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.

Authors:  Valérie Vilgrain; Helena Pereira; Eric Assenat; Boris Guiu; Alina Diana Ilonca; Georges-Philippe Pageaux; Annie Sibert; Mohamed Bouattour; Rachida Lebtahi; Wassim Allaham; Hélène Barraud; Valérie Laurent; Elodie Mathias; Jean-Pierre Bronowicki; Jean-Pierre Tasu; Rémy Perdrisot; Christine Silvain; René Gerolami; Olivier Mundler; Jean-Francois Seitz; Vincent Vidal; Christophe Aubé; Frédéric Oberti; Olivier Couturier; Isabelle Brenot-Rossi; Jean-Luc Raoul; Anthony Sarran; Charlotte Costentin; Emmanuel Itti; Alain Luciani; René Adam; Maïté Lewin; Didier Samuel; Maxime Ronot; Aurelia Dinut; Laurent Castera; Gilles Chatellier
Journal:  Lancet Oncol       Date:  2017-10-26       Impact factor: 41.316

6.  Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.

Authors:  Ruben Mujica-Mota; Jo Varley-Campbell; Irina Tikhonova; Chris Cooper; Ed Griffin; Marcela Haasova; Jaime Peters; Stefano Lucherini; Juan Talens-Bou; Linda Long; David Sherriff; Mark Napier; John Ramage; Martin Hoyle
Journal:  Health Technol Assess       Date:  2018-09       Impact factor: 4.014

7.  Cost-effectiveness of everolimus for the treatment of advanced neuroendocrine tumours of gastrointestinal or lung origin in Canada.

Authors:  A Chua; A Perrin; J F Ricci; M P Neary; M Thabane
Journal:  Curr Oncol       Date:  2018-02-28       Impact factor: 3.677

8.  Cost-Effectiveness Analysis of Selective Internal Radiotherapy With Yttrium-90 Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma.

Authors:  Kathryn E Marqueen; Edward Kim; Celina Ang; Madhu Mazumdar; Michael Buckstein; Bart S Ferket
Journal:  JCO Oncol Pract       Date:  2021-01-08

9.  Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma.

Authors:  Chi-Leung Chiang; Sik-Kwan Chan; Shing-Fung Lee; Irene Oi-Ling Wong; Horace Cheuk-Wai Choi
Journal:  JAMA Netw Open       Date:  2021-01-04

10.  Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France.

Authors:  Romaric Loffroy; Maxime Ronot; Michel Greget; Antoine Bouvier; Charles Mastier; Christian Sengel; Lambros Tselikas; Dirk Arnold; Geert Maleux; Jean-Pierre Pelage; Olivier Pellerin; Bora Peynircioglu; Bruno Sangro; Niklaus Schaefer; María Urdániz; Nathalie Kaufmann; José Ignacio Bilbao; Thomas Helmberger; Valérie Vilgrain
Journal:  Cardiovasc Intervent Radiol       Date:  2020-09-25       Impact factor: 2.740
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.